The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study)

A perspective and multicentric study to evaluate the efficacy of eptinezumab administered during a migraine attack. During the intravenous infusion of eptinezumab, some patients experiencing an ongoing migraine attack report its resolution. This finding is known in the literature, having been described in the RELIEF study. This study was designed to also evaluate, in a real-world setting, the efficacy of eptinezumab in resolving the ongoing attack and the time frame within which the attack is resolved. The study includes all patients who will begin treatment according to clinical practice, and are included in the TACHIS study (NCT06409845, Unique protocol ID RICe\_5)

NCT Number	NCT06628921
Lead Sponsor	University of Florence Collaborators: Società Italiana per lo Studio delle Cefalee, Fondazione Policlinico Universitario Campus Bio-Medico, SISC RICe Group
Conditions	Migraine
Enrollment	50 participants
Start Date	2024-10-30
Primary Completion	2026-10-30 (estimated)
Study Completion	2026-10-30 (estimated)
Updated on ClinicalTrials.gov	2026-01-21